We have built up specialist knowledge and expertise on RGD integrin drug discovery with an extensive publication track record. As the chemotypes are nearly always zwitterions they are atypical small molecules. We have experience in:

  • Delivering small molecule RGD integrin inhibitors of clinical quality
  • Experience of different modes of delivery (oral, iv, inhaled, long acting parenteral)
  • Expert knowledge of available integrin tools, probes for biological studies and screening assays
  • Application to the treatment of fibrotic diseases and cancer
  • Up-to-date competitor knowledge and patents

Integrin inhibitors we have contributed to designing and synthesising